Black Rock Mining receives top recovery marks

|

Published 13-NOV-2017 12:12 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

This product is classified as ‘very high risk’ in nature due to its location and geopolitical situation of the region. FinFeed advises that extra caution should be taken when deciding whether to engage in this product, however if you are not sure whether it is suitable for you we suggest you seek independent financial advice.

Tanazania-based Black Rock Mining (ASX:BKT) continues to make its case for a commercially-viable graphite operation in East Africa.

The ASX-listed junior explorer has announced news confirming both the high-grade nature of its Mahenge Project, but also, a high recharge rate from the pilot-test material BKT has provided for early feasibility testing.

Black Rock’s Mahenge Graphite Project has strongly outperformed a leading commercial brand in extended 300 cycle charge/discharge tests and its most recent results show a 94% recharge rate (commonly referred to as reversible capacity) over the period, outperforming industry standard products.

Importantly, the 300 cycles test is a benchmark for consumer products, as it represents a two-year product life with an assumed full discharge and recharge cycle every second day.

black rock mining recharge

Potentially the most significant benefit to BKT, is that by successfully negotiating the 300-cycle benchmark, BKT has effectively proved its Tanzanian graphite has sufficient properties to match the current consumer-product standard in lithium-ion batteries. Furthermore, the tests indicate that BKT will be able to deliver a two-year product life for consumer durables, with full discharge and recharge cycles every second day.

It should be noted however that BKT is a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

Following today’s news, BKT is already looking forward to further enhancing its recovery and recharge statistics. Data and methodology developed in the extended battery tests will be used to optimise second generation tests, further enhancing performance and stability.

Black Rock’s Executive Director and CEO John de Vries said, “To achieve a 94% recharge rate at 300 cycles on the first attempt to build a LiB battery is a remarkable result. In a market where performance is critical, we are the only graphite developer to have comprehensively demonstrated product performance. We believe we have the best natural flake graphite, and have done the work to prove it”.

“For Black Rock, the adoption of a long-term LiB battery cycle test program continues to validate our product, and provides a data rich starting point in our strategic objective to establish supply contracts with future customers. Feedback from existing and potential partners has been very positive, and importantly continued product development will remain a core part of our strategy and contributes towards de-risking our path to market,” he added.

tags

GRAPHITE


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X